short
halflif
drug
resist
crossreact
preexist
antibodi
hivinfect
patient
use
artifici
peptid
strategi
design
peptid
nonn
protein
sequenc
exhibit
potent
antivir
activ
broad
spectrum
strain
includ
resist
remark
longer
vivo
halflif
preexist
antibodi
hivinfect
patient
significantli
suppress
antivir
activ
antibodi
neither
recogn
attenu
activ
structur
differ
could
fold
singlehelix
interact
nhr
two
residu
met
thr
nterminu
form
hooklik
structur
stabil
interact
nhr
helic
therefor
potenti
develop
new
hiv
fusion
inhibitor
improv
antivir
efficaci
resist
profil
pharmacolog
properti
enfuvirtid
envelop
glycoprotein
env
human
immunodefici
viru
type
includ
surfac
subunit
transmembran
subunit
class
transmembran
protein
play
signific
role
membran
fusion
viru
entri
bind
cellular
receptor
undergo
conform
chang
fusion
peptid
fp
insert
sequenc
nhror
chrderiv
peptid
residu
correspond
nhr
pocket
region
mark
red
residu
pbd
mark
blue
mthook
residu
adjac
n
terminu
pbd
mark
green
peptid
consist
copi
artifici
sequenc
templat
aeelakk
underlin
mutant
residu
pbd
highlight
pink
b
inhibitori
activ
infect
iiib
subtyp
b
cell
left
panel
bal
subtyp
b
cell
right
panel
sampl
test
triplic
experi
repeat
twice
data
present
mean
sd
scientif
report
doi
address
obstacl
mani
effort
made
optim
chrderiv
peptid
peptid
better
inhibitori
activ
strain
andor
longer
halflif
howev
still
problem
crossreact
preexist
antibodi
sera
hivinfect
patient
contain
nativ
chr
sequenc
base
univers
artifici
peptid
templat
previous
design
artifici
peptid
made
preliminari
research
inhibitori
activ
envmedi
cellcel
fusion
present
studi
design
new
artifici
peptid
fig
aim
appli
mt
hook
structur
stabil
interact
artifici
peptid
hydrophob
pocket
nhr
trimer
comprehens
studi
antivir
activ
biochem
properti
crystal
structur
function
mechan
vivo
halflif
first
time
effect
preexist
antibodi
sera
hivinfect
patient
found
newli
design
artifici
peptid
exhibit
improv
antivir
activ
drug
resist
profil
pharmacolog
properti
particularli
preexist
antibodi
sera
hivinfect
patient
suppress
enhanc
activ
result
suggest
potenti
develop
new
antihiv
drug
confirm
strategi
use
design
artifici
antivir
peptid
envelop
virus
sarscov
merscov
paramyxoviru
inhibit
infect
higher
potenc
previous
design
artifici
peptid
could
inhibit
envmedi
cellcel
membran
fusion
colleagu
report
ad
two
amino
acid
met
thr
nterminu
chrpeptid
could
enhanc
activ
design
new
artifici
peptid
ad
met
thr
nterminu
fig
compar
activ
diverg
strain
includ
laboratoryadapt
virus
iiib
subtyp
b
bal
subtyp
b
seri
primari
isol
well
strain
shown
fig
exhibit
higher
inhibitori
activ
infect
iiib
bal
strain
ic
nm
respect
ic
nm
respect
ic
nm
respect
ic
nm
respect
inhibitori
activ
infect
diverg
primari
isol
distinct
genotyp
subtyp
e
group
phenotyp
also
higher
tabl
effect
strain
concentr
high
nm
could
effect
inhibit
infect
strain
ic
rang
nm
effect
tabl
result
indic
artifici
peptid
remark
improv
activ
broad
spectrum
strain
includ
variant
artifici
peptid
preexist
antibodi
patient
neither
recogn
attenu
activ
previou
studi
shown
preexist
antibodi
patient
includ
crossreact
specif
bind
site
eg
loop
region
eg
nhr
domain
could
significantli
block
fusion
inhibitori
activ
investig
influenc
preexist
antibodi
peptid
shown
fig
react
antibodi
sera
five
patient
howev
none
three
artifici
peptid
recogn
preexist
antibodi
inhibitori
activ
iiib
infect
reduc
presenc
sera
patient
fig
supplementari
tabl
confirm
preexist
antibodi
sera
hivaid
patient
attenu
activ
howev
none
artifici
peptid
present
studi
show
signific
decreas
activ
presenc
patient
sera
instead
antivir
activ
increas
presenc
antisera
patient
fig
supplementari
tabl
suggest
antibodi
actual
enhanc
activ
possibl
bind
antibodi
site
promot
interact
viral
nhr
region
longer
halflif
although
shown
efficaci
inhibit
infect
major
weak
lie
short
halflif
plasma
h
result
administ
subcutan
twice
daili
mg
per
dose
often
caus
seriou
injectionsit
reaction
perform
pharmacokinet
studi
intraven
administr
respect
sd
rat
dose
mgkg
order
compar
vivo
circul
time
expect
exhibit
shorter
halflif
lower
auc
system
circul
demonstr
much
higher
concentr
longer
circul
time
tabl
pharmacokinet
profil
fit
noncompart
model
pharmacokinet
paramet
calcul
pk
solver
vivo
elimin
halflif
h
longer
h
result
provid
theoret
basi
reduc
inject
frequenc
dose
fusion
inhibitor
conjug
improv
antivir
potenc
therefor
replac
may
significantli
reduc
injectionsit
reaction
drug
cost
would
promot
clinic
applic
hiv
fusion
inhibitor
resourcepoor
region
countri
much
resist
proteolyt
degrad
proteinas
k
rat
liver
homogen
compar
stabil
presenc
proteinas
k
broadspectrum
serin
proteinas
rat
liver
homogen
treatment
ngml
proteinas
k
h
parent
peptid
remain
detect
lcm
analysi
condit
retain
prototyp
fig
addit
show
significantli
enhanc
vitro
metabol
stabil
presenc
liver
homogen
fig
result
indic
artifici
peptid
much
resist
proteolyt
degrad
natur
peptid
may
contribut
signific
longer
vivo
halflif
describ
form
stabl
complex
block
format
investig
antivir
mechan
thermal
stabil
complex
compar
complex
circulardichro
cd
spectroscopi
lack
pocketbind
domain
pbd
complex
show
typic
helic
conform
consist
previou
studi
similar
helic
complex
complex
form
saddleshap
neg
peak
nm
nm
indic
helic
structur
fig
fig
indic
helic
complex
form
stabl
among
four
complex
compar
inhibitori
activ
format
sinc
block
format
use
smallmolecul
fusion
inhibitor
replac
control
inhibit
expect
could
effect
inhibit
format
ic
highli
effect
format
dosedepend
manner
ic
valu
potent
respect
fig
confirm
potent
block
fusion
core
format
thu
inhibit
fusion
target
cell
membran
structur
basi
potent
fusion
inhibitori
activ
artifici
peptid
elucid
molecular
determin
artifici
peptid
success
solv
three
complex
structur
peptid
bind
nhr
optim
linker
sampl
test
triplic
experi
repeat
twice
data
present
mean
sd
p
p
p
sggrgg
use
assembl
nhr
artifici
peptid
singl
recombin
protein
howev
similar
strategi
fail
crystal
therefor
decid
cocrystal
synthet
peptid
peptid
eventu
complex
crystal
obtain
interestingli
crystal
three
differ
inhibitor
belong
three
distinct
space
group
expect
nhr
portion
three
structur
form
trimer
core
portion
fold
singlehelix
conform
bind
nhrtrimer
form
typic
similar
core
structur
form
nativ
chr
peptid
fig
also
conserv
hydrophob
residu
artifici
peptid
deepli
buri
hydrophob
tabl
pharmacokinet
paramet
follow
intraven
administr
mgkg
male
sd
rat
n
figur
sensit
proteolyt
degrad
proteinas
k
rat
liver
homogen
digest
proteinas
k
ph
b
rat
liver
homogen
residu
amount
detect
lcm
analysi
experi
perform
triplic
data
present
mean
sd
inhibit
format
detect
elisa
use
mab
sampl
test
triplic
data
present
mean
sd
groov
form
pair
nhr
helic
similar
correspond
residu
nativ
chr
fig
ap
peptid
exhibit
better
affin
natur
chr
contain
natur
chr
sequenc
strong
interact
viral
nhrchr
complex
found
fig
howev
correspond
sequenc
hydrogen
bond
establish
correspond
chr
correspond
nhr
thu
play
role
stabil
interact
artifici
peptid
inhibitor
nhr
target
result
stronger
bind
affin
moreov
nhrchr
two
adjac
nhr
form
hydrophob
groov
buri
supplementari
fig
howev
correspond
chr
strongli
bind
fulli
hydrophob
side
chain
interact
similarli
interact
correspond
chr
correspond
nhr
respect
significantli
enhanc
supplementari
fig
like
chr
helix
helic
also
two
differ
side
hydrophob
side
face
toward
nhr
hydrophil
one
face
outward
expect
enhanc
hydrophil
expos
side
inhibitor
increas
antivir
activ
solubl
achiev
goal
amino
acid
residu
hydrophob
low
hydrophil
like
chr
chang
amino
acid
residu
high
hydrophil
like
respect
moreov
hydrophob
residu
chr
replac
hydrophil
residu
supplementari
fig
hydrophil
residu
glutam
acid
lysin
increas
solubl
whole
peptid
henc
stabil
complex
form
inhibitor
target
prove
eekk
doubl
salt
bridg
stabil
helix
conform
identifi
kind
interact
posit
three
complex
structur
interact
form
salt
bridg
network
interact
bind
bind
supplementari
fig
strong
salt
bridg
form
opposit
charg
residu
stabil
ap
peptid
conform
bring
inhibitori
effect
full
play
previous
report
addit
mt
hook
chr
peptid
sifuvertid
could
dramat
improv
activ
expect
ntermin
met
thr
form
hooklik
structur
fig
hydrophob
methionin
side
chain
accommod
groov
nhr
helic
cap
hydrophob
pocket
interact
lead
seri
conform
chang
main
chain
move
closer
nhr
compar
supplementari
fig
side
chain
flip
around
degre
buri
deeper
side
chain
turn
back
interact
side
chain
turn
back
interact
therefor
mt
hook
structur
could
stabil
bind
nhr
target
enfuvirtid
also
known
approv
us
fda
first
hiv
entri
inhibitorbas
antivir
drug
use
antihiv
medicin
treat
infect
adult
children
age
year
http
wwwfuzeoncom
although
indispens
antihiv
drug
hiv
aid
patient
fail
respond
current
antiretrovir
therapeut
shortcom
limit
clinic
applic
lower
antihiv
activ
shorter
halflif
chr
peptid
contain
pbd
addit
variant
emerg
shortli
eg
day
use
patient
virus
carri
mutat
giv
motif
residu
givqqqnnll
nhr
domain
lack
pbd
contribut
major
weak
describ
sinc
conserv
hydrophob
pocket
nhrtrimer
play
critic
role
stabil
interact
nhr
chr
format
fusogen
core
pbdcontain
chrpeptid
like
bind
viral
trimer
strongli
stabli
thu
possess
potent
antihiv
activ
chr
peptid
without
pbd
absenc
pbd
mainli
interact
middl
region
nhr
domain
contain
giv
motif
therefor
viru
mutat
motif
gener
resist
compar
antihiv
drug
anoth
weak
crossreact
preexist
antibodi
patient
besid
could
also
bind
region
preexist
antibodi
specif
bind
site
may
indirectli
suppress
antihiv
activ
addit
pbd
nterminu
could
significantli
improv
potenc
halflif
drugresist
profil
addit
mt
hook
structur
nterminu
pbdcontain
chrpeptid
mtsft
could
increas
activ
correspond
chrpeptid
delet
givmotifbind
domain
chrpeptid
anoth
effect
approach
increas
genet
barrier
drug
resist
howev
none
approach
effect
prevent
crossreact
preexist
antibodi
hivaid
patient
sinc
abovemodifi
peptid
mainli
contain
nativ
sequenc
chr
domain
previou
studi
shown
artifici
peptid
nonn
protein
sequenc
could
form
coiledcoil
structur
interact
nhr
inhibit
envmedi
cellcel
fusion
present
studi
design
new
artifici
peptid
ad
mt
hook
structur
nterminu
fig
follow
investig
influenc
preexist
antibodi
hivinfect
patient
use
control
demonstr
sera
hivinfect
patient
could
bind
significantli
reduc
potenc
howev
serum
sampl
interact
three
artifici
peptid
hardli
impair
antivir
activ
surprisingli
antibodi
sera
could
even
enhanc
activ
fig
b
supplementari
tabl
result
confirm
first
time
replac
nativ
viral
sequenc
artifici
sequenc
effect
approach
overcom
key
shortcom
wherebi
antihiv
activ
could
attenu
preexist
antibodi
hivaid
patient
worthwhil
explor
antibodi
sera
abl
enhanc
activ
recent
studi
demonstr
activ
enhanc
nonneutr
antibodi
direct
nhr
domain
thu
hypothes
antibodi
hivaid
patient
may
bind
site
nhr
domain
adjac
bind
region
result
increas
interact
nhrtrimer
enhanc
antivir
activ
compar
inhibitori
activ
mt
hook
without
mt
hook
infect
diverg
strain
effect
either
inhibit
infect
laboratoryadapt
strain
primari
isol
includ
resist
fig
tabl
one
may
question
whether
also
induc
drugresist
virus
patient
use
clinic
treat
hivinfect
patient
believ
expect
much
higher
genet
barrier
resist
contain
pbd
lack
pbd
dwyer
et
al
use
pbdcontain
chrpeptid
carri
passag
experi
use
control
demonstr
could
induc
mutant
viru
high
resist
month
fail
induc
resist
strain
month
cultur
extend
passag
experi
almost
month
identifi
one
strain
weak
resist
relat
mutat
site
pocket
region
suggest
pbdcontain
chrpeptid
includ
may
difficulti
induc
drugresist
also
longer
halflif
tabl
possibl
artifici
peptid
less
sensit
proteolyt
enzym
nativ
viral
protein
sequenc
remov
proteolyt
enzym
cleavag
site
peptid
expect
extend
halflif
result
confirm
replac
nativ
protein
sequenc
artifici
sequenc
addit
mt
hook
pbdcontain
peptid
sound
strategi
design
hiv
fusion
inhibitori
peptid
improv
antivir
activ
pharmacolog
properti
compar
sinc
threedimension
structur
ap
peptid
investig
present
studi
optim
artifici
peptid
inhibitor
could
perform
ration
structur
studi
artifici
peptid
complex
nhr
show
ap
peptid
like
chr
peptid
could
bind
nhr
form
canon
structur
fig
well
known
deep
hydrophob
pocket
exist
groov
surfac
viral
nhr
trimer
hydrophob
residu
chr
bind
hydrophob
residu
wall
pocket
result
format
stabl
strong
interact
chr
nhr
import
featur
well
preserv
structur
fig
may
account
potent
fusion
inhibitori
activ
artifici
peptid
new
hydrogen
bond
establish
complex
exist
viral
chrnhr
complex
suggest
may
play
import
role
stabil
interact
peptid
nhr
result
bind
affin
stronger
chr
nhr
furthermor
eekk
doubl
salt
bridg
form
posit
structur
could
stabil
helix
conform
increas
inhibitori
effect
peptid
compar
triplesit
mutat
introduc
ie
substitut
increas
solubl
peptid
also
trigger
seri
rearrang
certain
intrahel
salt
bridg
improv
stabil
chr
helix
structur
fusion
inhibitori
activ
mt
hook
previous
demonstr
effect
step
toward
increas
stabl
interact
chrpeptid
pocket
therefor
optim
incorpor
met
thr
nterminu
cd
spectroscopi
thermal
denatur
result
indic
incorpor
mt
hook
contribut
format
stabl
core
structur
mt
hookoptim
addit
eekk
doubl
salt
bridg
form
posit
structur
contribut
increas
chr
helix
stabil
result
improv
potenc
note
studi
chrpeptid
eekk
doubl
mutat
also
fusion
activ
halflif
may
strengthen
extend
respect
addit
mt
hook
design
conclus
artifici
peptid
pbd
mt
hook
structur
exhibit
improv
activ
drugresist
profil
well
prolong
halflif
moreov
react
preexist
antibodi
sera
hivaid
patient
consequ
antivir
activ
scientif
report
doi
significantli
affect
antibodi
therefor
show
promis
candid
develop
new
hiv
fusion
inhibitor
clinic
use
studi
also
provid
import
structur
activ
inform
ration
design
novel
artifici
peptid
inhibitor
besid
result
highlight
advantag
artifici
design
peptid
confirm
strategi
could
wide
use
develop
artifici
peptidebas
viru
fusion
inhibitor
envelop
virus
class
membran
fusion
protein
sarscov
merscov
paramyxoviru
ethic
statement
studi
involv
human
experiment
human
materi
use
serum
sampl
obtain
individu
approv
ethic
committe
shanghai
public
health
clinic
center
fudan
univers
protocol
method
carri
accord
approv
guidelin
sera
sampl
came
adult
minor
involv
studi
written
inform
consent
use
clinic
specimen
obtain
patient
involv
studi
peptid
synthesi
panel
peptid
fig
includ
well
nhrderiv
npeptid
synthes
standard
solidphas
fmoc
method
describ
previous
peptid
acetyl
n
terminu
amid
c
terminu
peptid
found
pure
hplc
identifi
mass
spectrometri
persept
biosystem
framingham
usa
concentr
peptid
determin
uv
absorb
theoret
calcul
molarextinct
coeffici
base
tryptophan
tyrosin
residu
qualif
assay
chromatograph
analys
perform
use
column
mm
mm
id
kept
ambient
temperatur
mobil
phase
compos
acetonitrilewaterform
acid
ratio
vvv
flow
rate
mlmin
sampl
inject
volum
l
acetonitril
hplc
grade
chemic
reagent
solvent
analyt
grade
thermo
tsq
quantum
discoveri
max
triplequadrupl
tandem
mass
spectromet
equip
esi
sourc
san
jose
ca
surveyor
lc
pump
use
lcm
analysi
data
acquisit
data
process
perform
use
xcalibur
softwar
lcquan
data
analysi
program
thermo
finnigan
respect
optim
ms
paramet
v
spray
voltag
psi
sheath
ga
pressur
psi
auxiliari
valv
flow
capillari
temperatur
run
collisioninduc
dissoci
cid
pressur
set
mtorr
select
reaction
monitor
srm
mode
use
select
ion
monitor
sim
mode
preform
follow
transit
record
mz
mz
mass
synthet
peptid
determin
malditofm
supplementari
fig
express
purif
fusion
protein
use
overlap
pcr
dna
fragment
encod
peptid
attach
cdna
nhr
short
linker
sggrgg
whole
sequenc
subclon
vector
novagen
usa
artifici
sumotag
ntermin
histag
target
protein
e
coli
cell
induc
ad
mm
iptg
incub
overnight
fusion
protein
purifi
ninta
affin
resin
qiagen
valencia
ca
usa
hissumotag
cleav
enzym
treatment
h
purifi
appli
onto
gel
filtrat
column
ge
healthcar
piscataway
nj
usa
fraction
contain
trimer
collect
concentr
differ
concentr
ultrafiltr
crystal
data
collect
structur
determin
fusion
protein
crystal
use
hang
drop
vapordiffus
method
drop
set
silicon
cover
clip
equilibr
mixtur
contain
l
protein
solut
mgml
trimer
mm
trishcl
ph
mm
nacl
l
reservoir
solut
trishcl
ph
wv
mgcl
l
reservoir
solut
one
week
singl
crystal
form
flash
frozen
liquid
nitrogen
futur
data
collect
fusion
protein
crystal
similar
way
differ
reservoir
solut
trishcl
ph
wv
mgcl
obtain
complex
crystal
nhr
synthes
first
mix
peptid
molar
ratio
appli
onto
gel
filtrat
column
ge
healthcar
piscataway
nj
usa
isol
form
fraction
contain
trimer
collect
concentr
mgml
crystal
use
hang
drop
vapordiffus
methodth
drop
set
silicon
cover
clip
equilibr
mixtur
contain
l
protein
solut
mm
trishcl
ph
mm
nacl
l
reservoir
solut
ammonium
sulfat
bistri
ph
wv
peg
l
reservoir
solut
day
singl
crystal
form
flash
frozen
liquid
nitrogen
futur
data
collect
dataset
collect
k
beamlin
advanc
photon
sourc
argonn
nation
laboratori
usa
dataset
collect
inhous
xray
sourc
micromax
xray
gener
rigaku
japan
institut
biophys
chineseacademi
scienc
dataset
complex
crystal
collect
beamlin
shanghai
synchrotron
radiat
facil
china
xray
diffract
data
integr
scale
use
program
phase
problem
three
structur
solv
molecular
replac
method
use
phenixphas
crystal
structur
hiv
nhrchr
pdb
entri
search
model
final
model
manual
adjust
coot
refin
phenixrefin
coordin
deposit
protein
data
bank
statist
data
collect
structur
refin
given
supplementari
tabl
determin
crossreact
nativ
artifici
peptid
preexist
antibodi
patient
sandwich
elisa
sandwich
elisa
conduct
determin
crossreact
peptid
preexist
antibodi
patient
coat
onto
well
polystyren
plate
costar
corn
inc
corn
ny
gml
well
block
gelatin
follow
addit
l
serial
dilut
sera
patient
incub
h
hrplabel
goatantihuman
igg
abcam
uk
tmb
ad
sequenti
determin
elisa
reader
ultra
tecan
patient
inhibit
peptid
iiib
subtyp
b
infect
presenc
patient
sera
determin
previous
describ
briefli
peptid
mix
serial
dilut
serum
patient
room
temperatur
min
next
mixtur
peptideserum
tcid
ad
cell
ml
rpmi
medium
contain
fb
incub
overnight
cultur
supernat
replac
fresh
cultur
medium
fourth
day
postinfect
cultur
supernat
collect
detect
antigen
elisa
cd
spectroscopi
thermal
midpoint
analysi
secondari
structur
peptid
mix
analyz
cd
spectroscopi
previous
describ
briefli
peptid
peptid
mixtur
dissolv
phosphatebuff
salin
pb
mm
sodium
phosphat
mm
nacl
ph
final
concentr
incub
min
cool
cd
spectra
sampl
acquir
jasco
spectropolarimet
model
jasco
inc
japan
use
nm
bandwidth
nm
resolut
cm
path
length
averag
time
sec
spectra
correct
subtract
blank
correspond
solvent
composit
sampl
thermal
midpoint
analysi
use
determin
temperatur
form
chr
nhr
would
decompos
monitor
nm
appli
thermal
gradient
melt
curv
smooth
midpoint
thermal
unfold
transit
tm
valu
calcul
use
jasco
softwar
util
describ
inhibit
sixhelix
bundl
format
sandwich
elisa
inhibit
sixhelix
bundl
format
test
peptid
determin
sandwich
elisa
describ
previous
briefli
test
peptid
control
grade
concentr
preincub
peptid
min
follow
addit
peptid
incub
anoth
min
mixtur
ad
polystyren
plate
costar
corn
inc
corn
ny
precoat
antibodi
gml
purifi
mous
antisera
specif
sixhelix
bundl
mab
hrplabel
rabbitantimous
igg
sigma
tmb
ad
order
determin
elisa
reader
ultra
tecan
inhibit
activ
infect
determin
previous
describ
inhibit
iiib
subtyp
b
tcid
viru
ad
ml
cell
rpmi
medium
contain
fb
presenc
absenc
test
peptid
overnight
cultur
supernat
chang
fresh
media
fourth
day
postinfect
cultur
supernat
collect
detect
antigen
elisa
inhibit
infect
strain
bal
subtyp
b
cell
ml
precultur
overnight
infect
bal
tcid
presenc
absenc
test
peptid
protein
overnight
cultur
supernat
chang
fresh
media
fourth
day
postinfect
cultur
supernat
discard
fresh
media
complement
supernat
collect
seventh
day
postinfect
test
antigen
elisa
previous
describ
percent
inhibit
product
calcul
analysi
halflif
peptid
inhibitor
four
male
sd
rat
weigh
approxim
g
obtain
shanghai
medic
school
anim
center
use
halflif
assay
anim
treat
accord
anim
welfar
act
guid
care
use
laboratori
anim
nih
public
revis
either
intraven
inject
concentr
mgml
inject
blood
sampl
acquir
rat
orbit
sever
time
point
min
h
peptid
inject
place
clean
tube
studi
pharmacokinet
rat
provid
experiment
evid
possibl
pharmacokinet
human
doubleantibodi
sandwich
elisa
method
establish
rapid
determin
rat
plasma
briefli
polystyren
plate
costar
corn
inc
corn
ny
precoat
antibodi
gml
purifi
rabbit
antisera
preincub
serum
sampl
dilut
time
h
follow
addit
antibodi
purifi
mous
antisera
specif
anoth
h
hrplabel
rabbitantimous
igg
sigma
usa
tmb
ad
order
absorb
nm
determin
elisa
reader
ultra
tecan
standard
peptid
paramet
obtain
first
plasma
peptid
concentr
determin
function
time
halflif
calcul
use
pk
solver
microsoft
excel
obtain
pharmacokinet
paramet
assess
sensit
peptid
proteolyt
digest
proteinas
k
proteolyt
enzym
liver
homogen
peptid
gml
prepar
pb
ph
contain
ngml
proteinas
k
result
mixtur
incub
water
bath
taken
differ
time
interv
minut
follow
quench
sampl
ethyl
alcohol
quantit
peptid
lcm
analysi
describ
test
sensit
peptid
proteolyt
enzym
liver
homogen
male
sd
rat
g
sacrif
anesthesia
whole
liver
quickli
remov
rat
wash
icecold
pb
mm
ph
weigh
cut
small
piec
resuspend
pb
mg
wet
liver
ml
pb
sampl
pool
homogen
follow
centrifug
g
min
supernat
collect
test
peptid
ad
liver
homogen
final
concentr
gml
result
mixtur
incub
water
bath
residu
peptid
mixtur
quantit
describ
